Impact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.contributor.authorAslan, Muzaffer
dc.contributor.authorOksen, Dogac
dc.contributor.authorKaynak, Cagdas
dc.contributor.authorOzudogru, Osman
dc.date.accessioned2024-12-24T19:24:11Z
dc.date.available2024-12-24T19:24:11Z
dc.date.issued2023
dc.departmentSiirt Üniversitesi
dc.description.abstractObjective Empagliflozin, an oral anti-diabetic drug that inhibits the sodium-dependent glucose co-transporter 2 (SGLT2), has pleiotropic effects on the myocardium. The aim of the study is to investigate the effect of empagliflozin on atrial electromechanical delay (AEMD) and the left atrial (LA) mechanical functions in patients with type 2 diabetes mellitus (DM). Method In total 62 patients (40.3% female, mean age 50.5 +/- 8.6 years old) with type 2 DM were enrolled to the study. Participants were used a SGLT2 inhibitor (empagliflozin 10-25 mg/daily) for 6 months. Patients were examined initially and after 6 months with echocardiography. LA volume was recorded, atrial conduction times were measured using tissue Doppler imaging (TDI). Results No significant change was observed in LA volumes (maximal, minimal, and presystolic), total emptying and passive emptying volume at the end of 6 months; however, there was a significant decrease in active emptying volume (8.3 +/- 2.9 ml/m(2) vs. 7.9 +/- 2.9 ml/m(2), p = 0.04). The posteroanterior lateral, septal, and tricuspid conduction times significantly decreased after the empagliflozin treatment. The decrease in right inter-AEMD was statistically significant (13.25 +/- 10.21 ms vs. 10.85 +/- 9.14 ms, p = 0.011). The changes in inter-AEMD were found to be correlated with the changes in LA active emptying volume (r = 0.408). Conclusion Empagliflozin may enhance the structure and electrical conductions of the atrium and may prevent DM patients from DM-2-related functional disorder and arrhythmia.
dc.identifier.doi10.1002/jcu.23384
dc.identifier.endpage404
dc.identifier.issn0091-2751
dc.identifier.issn1097-0096
dc.identifier.issue3
dc.identifier.pmid36308321
dc.identifier.scopus2-s2.0-85141390154
dc.identifier.scopusqualityQ3
dc.identifier.startpage398
dc.identifier.urihttps://doi.org/10.1002/jcu.23384
dc.identifier.urihttps://hdl.handle.net/20.500.12604/5888
dc.identifier.volume51
dc.identifier.wosWOS:000875690000001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Clinical Ultrasound
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241222
dc.subjectatrial electromechanical delay
dc.subjectdiabetes mellitus
dc.subjectempagliflozin
dc.subjecttissue Doppler echocardiography
dc.titleImpact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu